Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Budesonide HFA · 1 trial · 1 indication
Provocative concentration of methacholine is that causing a 20% fall in FEV1. The methacholine challenge test entailed the patient inhaling from an aerosol containing doubling concentrations of methacholine over a period of 2 minutes until FEV1 had been reduced by 20%. The ratio of Methacholine concentration measured at 2 weeks to that at Baseline.
| Arm | Type | Description |
|---|---|---|
| Budesonide Hydrofluoroalkane (HFA) 100 | ACTIVE_COMPARATOR | Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks |
| Budesonide HFA 400 | ACTIVE_COMPARATOR | Budesonide HFA 400 mcg twice daily for 2 weeks |
| Budesonide Chlorofluorocarbon (CFC) 100 | ACTIVE_COMPARATOR | Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks |
| Budesonide CFC 400 | ACTIVE_COMPARATOR | Budesonide CFC 400 mcg twice daily for 2 weeks |
| Name | Type | Description |
|---|---|---|
| Budesonide HFA | DRUG | standard daily inhaled dose |
| Budesonide CFC | DRUG | standard daily inhaled dose |
Inclusion Criteria: * Patients suffering from stable, persistent, mild to moderate asthma as defined by Global Initiative for Asthma (GINA) Guidelines and for whom FEV1 \> 60 % * ICS taking ≤ 1000 μg BDP per day, or equivalent * Methacholine PC20 \< 4 mg/mL Exclusion Criteria: * Known or suspecte...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Budesonide HFA is an inhaled corticosteroid formulation developed for the treatment of asthma. It is delivered as a hydrofluoroalkane (HFA) pressurized metered dose inhaler, studied in adults with mild to moderate asthma. The HFA propellant replaces the older chlorofluorocarbon propellant in the inhaler device.
Budesonide HFA targets NR3C1, the glucocorticoid receptor, and acts as an agonist at this receptor. Binding and activating NR3C1 produces the anti-inflammatory effects expected from an inhaled corticosteroid in the airways of asthma patients.
Budesonide HFA is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor associated with the clinical development program for this inhaled asthma product.
Budesonide HFA has been studied in Phase 3 clinical development. It is an investigational product and is not described as approved. The Phase 3 trial in the program has completed, and no active trials are currently listed for this asset.
Budesonide HFA was evaluated in the Phase 3 trial NCT00667992, titled a study comparing budesonide hydrofluoroalkane (HFA) versus chlorofluorocarbon (CFC) pressurized metered dose inhalers in patients with mild to moderate asthma. The trial enrolled 99 adults, was randomized and active controlled, and was conducted in the United States and the United Kingdom.